{"transactions":[{"id":983165,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-12-02T21:41:42.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan. The option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the option is 100% vested, which shall occur on the three-year anniversary of the date of grant."}],"balance_after":150000,"derivative":{"exercise_price":1.48,"expiration_date":"2035-11-23","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001213900-25-117305","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025117305/ownership.xml","form_type":"4"}},{"id":995092,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":1.5,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995091,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.92,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995090,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":32500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":32500,"derivative":{"exercise_price":1.5,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995089,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.05,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995088,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":35000,"derivative":{"exercise_price":1.5,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995087,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.74,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995086,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":35000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995085,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.92,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995084,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":19025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":19025,"derivative":{"exercise_price":1.5,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":19025},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995083,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":17.49,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":19025},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995082,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":15975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":15975,"derivative":{"exercise_price":1.5,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":15975},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995081,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":24.82,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":15975},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995080,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":108000,"derivative":{"exercise_price":1.5,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995079,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":3.91,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995078,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":108000,"derivative":{"exercise_price":1.5,"expiration_date":"2028-04-01","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":995077,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:31:54.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2028-04-01","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112241/ownership.xml","form_type":"4"}},{"id":1338590,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-12-09T21:00:26.000Z","date":"2024-12-05","kind":"grant","planned":false,"acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the 2021 Stock Incentive Plan. The option will become 100% vested and exercisable on December 5, 2026, the two-year anniversary of the grant date."}],"balance_after":32500,"derivative":{"exercise_price":5.05,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001213900-24-106914","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024106914/ownership.xml","form_type":"4"}},{"id":1513759,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-05-16T20:10:07.000Z","date":"2024-05-14","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the 2021 Stock Incentive Plan. The Option will become vested and exercisable 1/12th every month until the Option is 100% vested which shall occur on the one-year anniversary of the grant date."}],"balance_after":12500,"derivative":{"exercise_price":9.92,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001213900-24-044311","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024044311/ownership.xml","form_type":"4"}},{"id":1829376,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-14T20:05:08.000Z","date":"2023-07-12","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":11.0085,"value":110085.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 22, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares of common stock were sold in multiple transactions ranging from $11.00 to $11.10, inclusive. The reporting person undertakes to provide to Inmune Bio Inc., any security holder of Inmune Bio Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of common stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder. Mr. Schroeder has voting and investment control over these shares."}],"balance_after":82187,"source":{"system":"sec-edgar","filing":"0001213900-23-057083","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390023057083/ownership.xml","form_type":"4"}},{"id":2002764,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-02-21T21:07:12.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date."}],"balance_after":35000,"derivative":{"exercise_price":9.74,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-23-013282","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390023013282/ownership.xml","form_type":"4"}},{"id":2319807,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-03-23T20:31:14.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date."}],"balance_after":35000,"derivative":{"exercise_price":7.92,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-22-014505","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390022014505/ownership.xml","form_type":"4"}},{"id":2633756,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-14T20:07:13.000Z","date":"2021-07-13","kind":"sale","acquired":false,"shares":14480,"price":27.63,"value":400082.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 22, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $27.00 to $29.00, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of Common Stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder. Mr. Schroeder has voting and investment control over these shares."}],"balance_after":92187,"source":{"system":"sec-edgar","filing":"0001213900-21-036870","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390021036870/ownership.xml","form_type":"4"}},{"id":2635824,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-12T20:05:55.000Z","date":"2021-07-09","kind":"sale","acquired":false,"shares":30000,"price":23.205,"value":696150.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 22, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.00 to $25.25, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of Common Stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder. Mr. Schroeder has voting and investment control over these shares."}],"balance_after":106667,"source":{"system":"sec-edgar","filing":"0001213900-21-036518","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390021036518/ownership.xml","form_type":"4"}},{"id":2655474,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-06-24T21:58:08.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":19025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each Option represents a right to receive one share of common stock of INmune Bio, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options granted pursuant to the Company's 2021 Stock Incentive Plan. These Options vest on a pro rata quarterly basis over three years such that all options to purchase the 19,025 shares will have vested on the third anniversary of the grant date."}],"balance_after":19025,"derivative":{"exercise_price":17.49,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":19025},"source":{"system":"sec-edgar","filing":"0001213900-21-034016","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390021034016/ownership.xml","form_type":"4"}},{"id":2667545,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T20:09:41.000Z","date":"2021-06-14","kind":"sale","acquired":false,"shares":10000,"price":19.02,"value":190200.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $19.00 to $19.01, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of Common Stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder. Mr. Schroeder has voting and investment control over these shares."}],"balance_after":136667,"source":{"system":"sec-edgar","filing":"0001213900-21-032529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390021032529/ownership.xml","form_type":"4"}},{"id":2669606,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-14T20:22:46.000Z","date":"2021-06-10","kind":"sale","acquired":false,"shares":10000,"price":17.0054,"value":170054.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.00 to $17.04, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of Common Stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder. Mr. Schroeder has voting and investment control over these shares."}],"balance_after":146667,"source":{"system":"sec-edgar","filing":"0001213900-21-032300","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390021032300/ownership.xml","form_type":"4"}},{"id":2763307,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T20:31:49.000Z","date":"2021-03-31","kind":"sale","acquired":false,"shares":10000,"price":11.9496,"value":119496.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected in the open market outside of a 10b5 plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $11.59 to $12.47, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of Common Stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder. Mr. Schroeder has voting and investment control over these shares."}],"balance_after":156667,"source":{"system":"sec-edgar","filing":"0001213900-21-019674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390021019674/ownership.xml","form_type":"4"}},{"id":2900187,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-01-21T21:35:20.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":15975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each Option represents a right to receive one share of common stock of INmune Bio, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options granted pursuant to 2019 Stock Incentive Plan. Options shall vest on a pro rata quarterly basis over three years such that all options to purchase the 15,975 shares will have vested on the third anniversary of the grant date."}],"balance_after":15975,"derivative":{"exercise_price":24.82,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":15975},"source":{"system":"sec-edgar","filing":"0001213900-21-003485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390021003485/ownership.xml","form_type":"4"}},{"id":3357023,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":72354,"kind":"person","name":"Schroeder Timothy j","position":1,"cik":"0001767226","reported_name":"Schroeder Timothy j","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option","published_at":"2019-11-27T21:41:17.000Z","date":"2019-11-25","kind":"grant","acquired":true,"shares":108000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each Option represents a right to receive one share of common stock of INmune Bio, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant."}],"balance_after":216000,"derivative":{"exercise_price":3.91,"underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-19-024968","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390019024968/ownership.xml","form_type":"4"}}]}